https://bms-907351inhibitor.co....m/?p=1397preview=tru
In customers with risky conditions, the donor A/A or A/T genotype had been associated with much better 5 year overall survival (35% vs. 25%; p = 0.03) and 5 year disease-free survival (35% vs. 22%; p = 0.0072), compared to the donor T/T genotype. These effects weren't noticed in patients with low-risk diseases. The existing conclusions therefore indicate that HO-1 rs2071746 genotyping might be ideal for picking donors and tailoring transplant techniques for patients with high-risk hematologic malignancies.Short-chain quinones (SC
Like
Comment
Share
